VRTX · 10-Q · 2026Q2 · Full report
Acquisition / Partnership / Divestiture
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 71 · Surprise 60 · Contradicted
In July 2026, Vertex entered into an agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing an approximately $10.0 billion equity value. The transaction is expected to close in the third quarter of 2026, subject to customary conditions. Vertex plans to fund the acquisition with cash, cash equivalents and proceeds from a new $4.5 billion term loan. Crinetics adds FDA- and EMA-approved PALSONIFY and the Phase 3 atumelnant program to Vertex’s endocrine-disease portfolio.
Key facts
- Entered agreement and plan of merger to acquire Crinetics for $85.00 per share in cash for a total equity value of approximately $10.0 billion in July 2026; expect transaction to close in the third quarter of 2026, subject to customary conditions source
- In 2024 acquired Alpine Immune Sciences and povetacicept for approximately $5.0 billion; accounted as asset acquisition and expensed $4.4 billion as AIPR&D in 2024 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | probable | +18.2% | Entered agreement and plan of merger to acquire Crinetics for $85.00 per share in cash for a total equity value of approximately $10.0… |